White & Case Advised Berenberg on BioNTech’s public exchange offer for CureVac shares
White & Case Advised Berenberg on BioNTech’s public exchange offer for CureVac shares
Global law firm White & Case LLP has advised Joh. Berenberg, Gossler & Co. KG. (Berenberg) in connection with BioNTech SE's (BioNTech) public exchange offer for all outstanding shares in CureVac N.V. (CureVac).
Under the terms of the transaction, each CureVac share will be exchanged for approximately US$5.46 in BioNTech ADSs, resulting in an implied aggregate equity value for CureVac of approximately US$1.25 billion. Berenberg is acting as subscription agent for the public exchange offer.
The White & Case team in Frankfurt which advised on the transaction included Gernot Wagner (Partner), Yannick Adler (Partner) and Alexander Kiefner (Partner), Timo Lockemann (Local Partner) and Zgjim Mikullovci (International Attorney).
If you have a news or deal publication or would like to collaborate on content, columns, or article publications, connect with the Legal Era News Network Team and email us at info@legalera.in or call us on +91 8879634922.
